NOX4 and prostate cancer: An in vitro study has shown that the imbalance of redox homeostasis caused by elevated NOX4-derived ROS signal was the basis of fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma, which indicates NOX4 inhibitors have potential clinical value in the prevention of BPH and prostate cancer [106].